Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15572838 | 0.82 | CA12 (0.41) | CA12CA7CA14LMNATSHR | |
| SCHEMBL29926166 | 0.80 | CA12 (0.39) | CA12CA7CA14LMNATSHR | |
| SCHEMBL3255917 | 0.80 | CA12 (0.39) | CA12CA7CA14LMNATSHR | |
| SCHEMBL49152 | 0.80 | CA12 (0.39) | CA12CA7CA14LMNATSHR | |
| Potassium Ion SCHEMBL8985015 | 0.78 | CA12 (0.38) | CA12CA7CA14LMNATSHR | |
| SCHEMBL5492629 | 0.78 | CA12 (0.38) | CA12CA7CA14LMNATSHR | |
| Water SCHEMBL730524 | 0.78 | CA12 (0.38) | CA12CA7CA14LMNATSHR | |
| SCHEMBL5497675 | 0.78 | L3MBTL1 (0.38) | CA12CA7CA14LMNATSHR | |
| SCHEMBL4566523 | 0.78 | CA12 (0.38) | CA12CA7CA14LMNATSHR | |
| SCHEMBL5492640 | 0.78 | CA12 (0.38) | CA12CA7CA14LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269137-A1 | HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHY | TENAYA THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| EP-3233085-B1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF EGFR AND PI3K | UNIV MICHIGAN REGENTS (US) | 2022-09-07 | — | — | EP | disclosed |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-06 | — | — | US | disclosed |
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
| EP-3102203-A2 | ANTIBACTERIAL COMBINATIONS COMPRISING POLYMYXIN | SPERO GYRASE, INC. (US) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015114452-A2 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2015-08-06 | — | — | WO | disclosed |
| EP-1888581-A2 | HIV-INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125048-A2 | HIV-INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20050261332-A1 | Sulfonamides and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | CA12 4398/4885CA7 2787/4885CA14 4200/4885 |
| US-20240269137-A1 | HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHY | HDAC6, HDAC1, HDAC2 | CA12 4008/4885CA7 3221/4885CA14 4071/4885 |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | CA12 4398/4885CA7 2787/4885CA14 4200/4885 |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | CA12 4398/4885CA7 2787/4885CA14 4200/4885 |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | CA12 4398/4885CA7 2787/4885CA14 4200/4885 |
| US-20050261332-A1 | Sulfonamides and uses thereof | GLS2, STS, ABAT | CA12 1474/4885CA7 2571/4885CA14 1010/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | CA12 3176/4885CA7 3412/4885CA14 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.